期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 15, 期 5, 页码 268-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.27
关键词
-
类别
Patients value anticancer therapies that provide durable clinical responses; immune-checkpoint inhibitors can provide such benefit for patients with some advanced-stage malignancies, albeit only for a minority of those treated. Modern oncology value frameworks have set efficacy thresholds in an attempt to assess the clinical benefit of anticancer therapeutics. But, is the benefit of durable cancer control reflected in these thresholds?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据